Price movement over the last 24 hours
ADMA Biologics Inc vs Badger Meter Inc — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Badger Meter Inc trades at $145.55 (market cap $4.37B). The key difference: Badger Meter Inc is far larger — about 2.1× ADMA Biologics Inc's market cap, and Badger Meter Inc pays a 1.07% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BMI | |
|---|---|---|
Market Cap | $2.13B | $4.37B |
Sector | Health | Technology |
52-Week High | $20.38 | $245.81 |
52-Week Low | $7.60 | $113.41 |
Enterprise Value | $2.20B | $4.17B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Badger Meter (BMI) trades at $149.79, up 2.69% with a bullish technical signal from moving averages. The company maintains strong profitability with 14.56% net income margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create headwinds. Valuation metrics show a P/E of 33.89 and P/S of 4.93, above industry averages.
While BMI demonstrates solid fundamentals and technical strength, the stock faces significant legal risks from multiple class action lawsuits alleging securities fraud. Analyst consensus is mixed with 28% buy ratings but a $144.80 price target below current levels. The combination of legal overhang and premium valuation creates a cautious near-term outlook despite strong operational performance.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →